VEGFA and neoplasm: More diffuse, infiltrative, non-enhancing tumour at progression as well as the emergence of new, distant CNS sites of disease suggest that malignant gliomas may evolve resistance to VEGF-targeted therapeutics by adopting a more invasive phenotype that is relatively independent of VEGF signalling.